BIO CEO 2012 Therapeutic Workshop: Cardiology

  • Recommend
  • Tweet
  • Print
  • Email

Shot to the Heart—The Race to Conquer Dyslipidemia/Hypercholesterolemia

Tuesday, February 14th, 1:15pm-2:10pm

With $36.4 billion in worldwide sales last year alone, according to IMS Health, the business of lowering LDL and raising HDL, is well, big business. With Lipitor’s patent life gone, a novel, effective and safe substitute could be just the answer that pharma and select biotechs are looking for to propel blockbuster sales.  CETP inhibitors are showing promise but could lingering safety issues prove detrimental to further development? A unique MTP inhibitor is also in play with a possible launch in early 2013. Experts will convene to discuss the pipeline development for lowering LDL and raising HDL.

Moderator:

  • Michael J. Haas, Senior Writer, BioCentury Publications, Inc.

Panelists:

  • Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals, Inc.
  • Ram Y. Gordon, MD, Clinical Cardiologist, University of Pennsylvania
  • Michael C. Kim, MD, Director of the Coronary Care Unit & Director of Medical Education in the Cardiac Catheterization Laboratory, Mount Sinai Hospital
  • Donald A. Smith, MD, Associate Professor Cardiology & Preventative Medicine, Mount Sinai Hospital

Who's Who


Marc Beer
Chief Executive Officer, Aegerion Pharmaceuticals,  Inc.
Marc Beer is the Chief Executive Officer of Aegerion (AEGR). Aegerion Pharmaceuticals is focused on the commercialization of life-altering therapy for debilitating and fatal orphan diseases. Marc took Aegerion public in October, 2010. Marc brings over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000, Marc became the founding CEO of Viacell (VIAC), a biotechnology company specializing in the collection, preservation and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI). Prior to founding Viacell, Marc held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts. Marc serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board as well as on the board of directors of Good Start Genetics, Inc. where he is Chairman; Seaside Therapeutics, Inc. and ERYtech Pharma. Marc holds a B.S. from Miami University (Ohio).

Ram Y. Gordon, MD

Clinical Cardiologist, University of Pennsylvania
Dr. Gordon was raised in Pittsburgh, Pennsylvania and attended the University of Pennsylvania as an undergraduate, majoring in English and American history. He studied medicine at the University of Pittsburgh School of Medicine, where he served as president of his class for two years, received the senior award for excellence in medicine, and graduated as a member of the Alpha Omega Alpha honor society.

Dr. Gordon completed his residency and chief residency in the Department of Medicine at the Hospital of the University of Pennsylvania. During his residency, he received the Humaneness in Medicine award from the Philadelphia County Medical Society and the Penn Pearls award from the University of Pennsylvania School of Medicine for outstanding teaching of medical students. He then completed a fellowship at Mount Sinai in New York City, where he served as chief fellow during his senior year.

Dr. Gordon joined the staff of Chestnut Hill Hospital, part of the University of Pennsylvania Health System, in 2005. He is board certified in internal medicine, cardiovascular diseases, and nuclear cardiology. His interests include atherosclerotic heart disease, valvular heart disease, preventative cardiology, and hyperlipidemia. Dr. Gordon has lectured on a variety of topics related to cardiology and has been an author on several peer-reviewed papers studying the use of alternative therapies for the treatment of high cholesterol. He has also written several essays related to humanism in medicine that have been published in JAMA and The New York Times Well Blog. He was awarded the Golden Apple by the housestaff of Chestnut Hill Hospital in 2007 and 2008 for excellence in teaching.

When Dr. Gordon is not working he enjoys spending time with his wife and 3 young children. His interests include running, cooking, sports, and traveling.

Michael J. Haas
Senior Writer, BioCentury Publications, Inc.
Mike, who serves as a Senior Writer at BioCentury, has nearly 14 years of experience as an analytical chemist and mass spectrometry group leader at DuPont, DuPont Merck, DuPont Pharma and Bristol-Myers Squibb. He holds an M.Sc. in chemistry from the University of Toronto and a B.S. in chemistry from the University of Delaware.

Donald A. Smith, MD
Associate Professor Cardiology & Preventative Medicine, Mount Sinai Hospital
Dr. Smith is the only endocrinologist associated with the Zena and Michael A. Wiener Cardiovascular Institute, and Marie-Josee and Henry R. Kravis Center for Cardiovascular Health. His major interest in this role is in the prevention of thromboembolic atherosclerotic cardiovascular disease, such as heart attacks, strokes and peripheral vascular disease. His particular clinical interest is primarily in lipid disorders, but also involves diabetes, and obesity. By controlling such risk factors in individuals, one can reduce one's long-term risk for such diseases.

Dr. Smith writes extensively concerning lipid disorders and has just complete editing a fourteen-chapter, 2-volume issue of Clinics in Laboratory Medicine on Risk Factors in Atherosclerotic Cardiovascular Disease. He just had published a comprehensive article on statin therapy for Current Molecular Medicine.

His research has been predominantly involvement in numerous clinical trials most of which have involved lowering cholesterol with statins to show the preventive efficacy and safety of these medications. Other studies have involved measuring the improvement in physicians' ability to lower cholesterol levels as progress has been made in this area, and the lack of improvement in such behavior in simply providing electronic tools to track patient progress. He has also studied various measures of obesity in their relative ability to predict coronary heart disease.

He is an active member of the American Diabetes Association and the American Heart Association. He is currently Treasurer and a Board member of the Northeast Lipid Association, an important regional association of the National Lipid Association, a group interested in educating physicians on how best to manage lipid (cholesterol/triglyceride) disorders. In February 2006 he was CoChairman of the annual scientific session of the National Lipid Association.

He is an active member of the American Association of Clinical Endocrinologists and has been a member of the writing groups involved in guidelines on the metabolic syndrome and on lipids. He is also the current lipid's section editor for the Association's Self-Assessment Profile in Endocrinology and Metabolism.